EUVIMEDEUVIMED entdecken
Crossref

Real-world pharmacokinetics of trametinib in pediatric low-grade glioma

Laurie Pagnot, Isaline Granger, Jérôme Guitton, Bertrand Favier, Antony Ceraulo, Cécile Faure-Conter, Pierre Leblond, Michael Philippe

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04761-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Laurie Pagnot und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Oncology, Centre Leon Bérard, Lyon, France. Hauptthemen laut MEDLINE: Pyridones, Pyrimidinones, Glioma, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Trametinib, a MEK1/2 inhibitor, has emerged as a promising treatment for pediatric patients with low-grade gliomas (LGG). However, trametinib exhibits significant inter-individual pharmacokinetic (PK) variability, and studies in adults demonstrated an exposure-efficacy relationship. This study aimed to evaluate the PK profile of trametinib in pediatric routine care and explore potential exposure-outcome relationships. METHODS: We analyzed PK data from 65 blood samples from 19 children receiving trametinib, either as single agent or in combination with dabrafenib. A trough concentration (Cmin) range of 8-15 ng/mL was considered, based on average exposure reported in the largest pediatric study. RESULTS: The mean Cmin was 8.82 ng/ml, with 64.6% of samples falling within the predefined target range, while 35.4% were below it. Regarding tolerance, 84.2% of patients experienced treatment-related toxicities, predominantly skin and subcutaneous tissue disorders. Efficacy data were limited. CONCLUSION: These findings underscore the necessity of therapeutic drug monitoring in pediatric patients to optimize treatment efficacy and minimize toxicity, highlighting trametinib's potential for personalized dosing strategies in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesPyrimidinonesGliomaBrain NeoplasmsProtein Kinase InhibitorsHumansChildMaleFemaleAdolescentChild, PreschoolOximesDrug MonitoringImidazolesAntineoplastic Combined Chemotherapy ProtocolsInfant

Stichwörter der Autor:innen

Low-grade gliomaPediatric cancerPharmacokineticsTrametinib

Substanzen

trametinibPyridonesPyrimidinonesdabrafenibOximesImidazolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Oncology, Centre Leon Bérard, Lyon, France.
  • Biochemistry and Pharmacology-Toxicology Laboratory, Lyon Sud Hospital, Pierre Bénite, France.
  • Institute of Pediatric Hematology and Oncology (IHOPe), Centre Léon Bérard, Lyon, France.
  • Department of Clinical Pharmacy and Oncology, Centre Leon Bérard, Lyon, France. michael.philippe@lyon.unicancer.fr.
  • Institute of Pediatric Hematology and Oncology (IHOPe), Centre Léon Bérard, Lyon, France. michael.philippe@lyon.unicancer.fr.

Zitieren

APA

Pagnot, L., Granger, I., Guitton, J., Favier, B., Ceraulo, A., Faure-Conter, C., Leblond, P., & Philippe, M. (2025). Real-world pharmacokinetics of trametinib in pediatric low-grade glioma. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04761-0

Vancouver

Pagnot L, Granger I, Guitton J, Favier B, Ceraulo A, Faure-Conter C, et al. Real-world pharmacokinetics of trametinib in pediatric low-grade glioma. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04761-0

BibTeX
@article{Pagnot2025,
  author = {Pagnot, Laurie and Granger, Isaline and Guitton, Jérôme and Favier, Bertrand and Ceraulo, Antony and Faure-Conter, Cécile and Leblond, Pierre and Philippe, Michael},
  title = {Real-world pharmacokinetics of trametinib in pediatric low-grade glioma},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04761-0}
}
Kostenlos starten →